# Olema Pharmaceuticals, Inc. (OLMA) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/OLMA
## Company Profile
- Ticker: OLMA
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Oncology
## Stock Data
- Close: 11.58 USD
- Market cap: 933744464.99 USD
- Last updated: 2026-08-05
## Business Overview
### Endocrine-Driven Cancer Company
Olema Oncology develops targeted therapies based on estrogen receptor biology, nuclear receptors, and resistance mechanisms in breast cancer.
### Palazestrant
Palazestrant is an oral complete estrogen receptor antagonist being studied as monotherapy and in combinations for ER-positive, HER2-negative breast cancer.
### OP-3136
OP-3136 is an oral KAT6 inhibitor intended to complement endocrine therapy and address transcriptional drivers of resistance.
## Why The Stock Is Moving

The latest company update was “Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)”. OLMA changed 1.53% and closed at $11.58 on Aug 5, 2026, indicating a relatively limited closing-price reaction to this company update.

## Future Catalysts

- Topline results from the Phase 3 OPERA-01 palazestrant study are expected in fall 2026.
- Initial Phase 1 clinical data for OP-3136 are scheduled for presentation at ASCO 2026.

## Drug Assets

- OP-3136

## Recent News
- 2026-08-04 20:30 EST — [Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/OLMA/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-0d4c3b30) — Source: Olema Pharmaceuticals, Inc.
- 2026-05-26 11:00 EST — [Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer](https://biopharmsignal.com/news/OLMA/olema-oncology-announces-clinical-trial-collaboration-and-supply-agreement-with-bayer-to-evaluate-op-3136-in-combination-with-nubeqar-darolutamide-in-metastatic-castration-resistant-prostate-cancer) — Source: Olema Pharmaceuticals, Inc.
- 2026-05-21 21:00 EST — [Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting](https://biopharmsignal.com/news/OLMA/olema-oncology-announces-encouraging-initial-clinical-data-from-the-phase-1-study-of-op-3136-a-kat6-inhibitor-at-2026-asco-annual-meeting) — Source: Olema Pharmaceuticals, Inc.
- 2026-05-19 20:30 EST — [Olema Oncology to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/OLMA/olema-oncology-to-participate-in-upcoming-investor-conferences-8b939a2f) — Source: Olema Pharmaceuticals, Inc.
- 2026-05-12 11:00 EST — [Olema Oncology Reports First Quarter 2026 Financial and Operating Results](https://biopharmsignal.com/news/OLMA/olema-oncology-reports-first-quarter-2026-financial-and-operating-results) — Source: Olema Pharmaceuticals, Inc.